Physician profile
Aseem Ali
NPI 1508338146
$3,770.47
in general payments reported to CMS, 2019-2025
21 companies · $962 in 2025
The $962 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,580 · 2022: $1,052 · 2023: $176 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.45 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $465.28 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $392.40 | 2021-2025 | Trintellix |
| Corium, LLC | $306.01 | 2021-2023 | Azstarys |
| Lundbeck LLC | $302.62 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $212.39 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $204.26 | 2021-2025 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $198.73 | 2025 | Spravato |
| Neurocrine Biosciences, INC. | $175.64 | 2021-2025 | |
| Tris Pharma INC | $130.23 | 2022-2025 | Onyda Xr, Dyanavel Xr |
| Neos Therapeutics, LP | $123.82 | 2021-2022 | |
| Eisai INC. | $106.89 | 2021 | |
| Supernus Pharmaceuticals, INC. | $105.45 | 2021-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.81 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $79.51 | 2022-2025 | Austedo Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $76.15 | 2025 | Auvelity |
| Alkermes, INC. | $59.17 | 2021-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $53.72 | 2023 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $37.58 | 2022-2023 | Subvenite, Lamotrigine |
| Aytu Biopharma, INC. | $18.28 | 2021 | |
| Merck Sharp & Dohme LLC | $18.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aseem Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.